However, therapies combining HDAC inhibitors with additional anti-cancer drugs as chemotherapeutics or targeted therapies seem to be more attractive, as synergistic or additive anti-tumor effects have been reported for several cancer entities in preclinical studies as well as in phase I clinical trials [20,53,54]. The gene discussed is HDAC9; the disease is neoplasm.